CLAIMS

1. A composition comprising capivasertib and a composition comprising fulvestrant for use as a combination therapy in the treatment of a patient having hormone receptor-positive (HR+) breast cancer, wherein the patient's tumour cells do not comprise any of the following mutations:

i. E17K in the AKT1 gene;
ii. Any of the mutations in the PIK3CA gene listed in Table 2; and
iii. Any of the mutations in the PTEN gene listed in Table 3 or in Table 4.

2. A composition comprising capivasertib and a composition comprising fulvestrant for use according to claim 1, wherein the patient has estrogen receptor-positive (ER+) breast cancer.

3. A composition comprising capivasertib and a composition comprising fulvestrant for use according to claim 1 or claim 2, wherein the patient has an aromatase inhibitor-resistant breast cancer.

4. A composition comprising capivasertib and a composition comprising fulvestrant for use according to any preceding claim, wherein the patient has a HER2-negative breast cancer.

5. A composition comprising capivasertib and a composition comprising fulvestrant for use according to any preceding claim, wherein the composition comprising capivasertib and the composition comprising fulvestrant are to be administered separately.

6. Use of capivasertib in the manufacture of a medicament for treating a patient having hormone receptor-positive (HR+) breast cancer, wherein the capivasertib is to be administered in combination with fulvestrant, wherein the patient's tumour cells do not comprise any of the following mutations:

i. E17K in the AKT1 gene;
ii. Any of the mutations in the PIK3CA gene listed in Table 2; and
iii. Any of the mutations in the PTEN gene listed in Table 3 or in Table 4.

7. The use according to claim 6, wherein the patient has estrogen receptor-positive (ER+) breast cancer.

8. The use according to claim 6 or claim 7, wherein the patient has an aromatase inhibitor-resistant breast cancer.

9. The use according to any of claims 6 to 8, wherein the patient has a HER2-negative breast cancer.

10. The use according to any of claims 6 to 9, wherein capivasertib and fulvestrant are to be administered separately.